Skip to main content
    U

    United Therapeutics Corporation (UTHR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $587.88
    -3.29 (-0.56%)

    Market Cap: $25.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    United Therapeutics Corporation (UTHR) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    United Therapeutics (UTHR) trades at 22.2x trailing earnings and 7.9x sales. Its P/E of 22.2x is above its 5-year median of 14.6x. Its forward P/E is 18.7x. The median P/E across 9 similar companies is 18.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 18.7% higher over the next year. Its free cash flow yield is 3.5%.

    MultipleValue
    P/E (trailing)22.2x
    Forward P/E18.7x
    Price to sales7.9x
    Price to book4.0x
    EV/EBITDA16.3x
    Price to FCF28.9x
    EV/FCF27.6x
    PEG2.2
    FCF yield3.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 79.0% above 12.4x, its P/S is 71.7% above 4.6x and its P/B is 81.8% above 2.2x.

    MultipleCurrent5-year median10-year median
    P/E22.2x14.6x12.4x
    P/S7.9x5.6x4.6x
    P/B4.0x2.4x2.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 108 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 8.9x in 2017 to 17.5x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$487.2517.5x6.9x3.3x
    2024$352.8414.0x5.7x2.7x
    2023$219.8911.1x4.5x1.8x
    2022$278.0917.3x6.7x2.9x
    2021$216.0816.2x5.8x2.6x
    2020$151.7911.4x4.6x2.0x
    2019$88.08N/A2.7x1.4x
    2018$108.909.1x2.9x1.7x
    2017$147.958.9x3.8x3.1x
    2016$143.4310.1x4.0x3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About UTHR

    What is UTHR's forward P/E ratio?

    United Therapeutics has a forward P/E ratio of 18.7x.

    Is UTHR stock overvalued?

    GNG's valuation label for UTHR is Fairly valued. Its P/E of 22.2x compares with a median of 18.4x across 9 similar companies.

    What is UTHR's price to sales ratio?

    United Therapeutics has a price to sales ratio of 7.9x.

    What is United Therapeutics's average P/E ratio over 5 years?

    United Therapeutics's median P/E over the last 5 years is 14.6x, from 60 month-end values through Oct 2026.

    What is UTHR's PEG ratio?

    United Therapeutics has a PEG ratio of 2.2.